B
71.72
1.09 (1.54%)
| Previous Close | 70.63 |
| Open | 70.98 |
| Volume | 1,620,320 |
| Avg. Volume (3M) | 2,430,735 |
| Market Cap | 13,821,076,480 |
| Price / Sales | 38.03 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Operating Margin (TTM) | -89.00% |
| Diluted EPS (TTM) | -3.56 |
| Quarterly Revenue Growth (YOY) | -44.80% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -500.42 M |
| Levered Free Cash Flow (TTM) | -261.20 M |
| Return on Assets (TTM) | -48.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
AIStockmoo Score
0.0
| Analyst Consensus | 1.5 |
| Insider Activity | -5.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.00 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.97% |
| % Held by Institutions | 98.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aisling Capital Management Lp | 30 Sep 2025 | 6,089,611 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (Cantor Fitzgerald, 53.37%) | Buy |
| Median | 87.00 (21.31%) | |
| Low | 71.00 (Raymond James, -1.00%) | Buy |
| Average | 88.70 (23.68%) | |
| Total | 10 Buy | |
| Avg. Price @ Call | 62.11 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 11 Nov 2025 | 84.00 (17.12%) | Buy | 66.58 |
| JP Morgan | 07 Nov 2025 | 77.00 (7.36%) | Buy | 61.80 |
| 03 Sep 2025 | 70.00 (-2.40%) | Buy | 51.84 | |
| HC Wainwright & Co. | 03 Nov 2025 | 90.00 (25.49%) | Buy | 61.98 |
| 29 Oct 2025 | 90.00 (25.49%) | Buy | 66.62 | |
| Goldman Sachs | 31 Oct 2025 | 100.00 (39.43%) | Buy | 62.64 |
| Cantor Fitzgerald | 30 Oct 2025 | 110.00 (53.37%) | Buy | 63.37 |
| Piper Sandler | 30 Oct 2025 | 98.00 (36.64%) | Buy | 63.37 |
| Raymond James | 30 Oct 2025 | 71.00 (-1.00%) | Buy | 63.37 |
| 21 Oct 2025 | 59.00 (-17.74%) | Buy | 54.36 | |
| TD Cowen | 30 Oct 2025 | 95.00 (32.46%) | Buy | 63.37 |
| Truist Securities | 30 Oct 2025 | 80.00 (11.54%) | Buy | 63.37 |
| UBS | 12 Sep 2025 | 82.00 (14.33%) | Buy | 51.21 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| APULI MARICEL | - | 66.39 | -4,781 | -317,411 |
| KUMAR NEIL | - | 66.39 | -32,855 | -2,181,243 |
| LO ANDREW | - | 66.25 | -95,599 | -6,323,523 |
| SCOTT RANDAL W. | - | 66.90 | -10,000 | -669,000 |
| TRIMARCHI THOMAS | - | 66.65 | -38,251 | -2,548,120 |
| Aggregate Net Quantity | -181,486 | |||
| Aggregate Net Value ($) | -12,039,297 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 66.49 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LO ANDREW | Director | 18 Nov 2025 | Sell (-) | 55,000 | 65.59 | 3,607,450 |
| TRIMARCHI THOMAS | Officer | 17 Nov 2025 | Automatic sell (-) | 16,934 | 66.90 | 1,132,885 |
| SCOTT RANDAL W. | Director | 17 Nov 2025 | Automatic sell (-) | 10,000 | 66.90 | 669,000 |
| SCOTT RANDAL W. | Director | 17 Nov 2025 | Option execute | 10,000 | - | - |
| LO ANDREW | Director | 17 Nov 2025 | Sell (-) | 40,599 | 66.90 | 2,716,073 |
| APULI MARICEL | Officer | 16 Nov 2025 | Disposed (-) | 4,781 | 66.39 | 317,411 |
| TRIMARCHI THOMAS | Officer | 16 Nov 2025 | Disposed (-) | 21,317 | 66.39 | 1,415,236 |
| KUMAR NEIL | Officer | 16 Nov 2025 | Disposed (-) | 32,855 | 66.39 | 2,181,243 |
| KUMAR NEIL | Officer | 16 Nov 2025 | Option execute | 64,697 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |